ArticleScientific reports2025
Identification of potential molecular targets of rhaponticin in the treatment of periodontitis using bioinformatics tools.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
The aim of this study was to investigate the potential mechanisms of Rhaponticin (Rha) in the treatment of periodontitis. Network pharmacology and molecular docking techniques were used to identify potential targets of Rha for the treatment of periodontitis and its ability to bind to the targets. Next, in vitro as well as in vivo experiments were conducted to validate Rha's potential role in treating periodontitis. We found in network pharmacology and molecular docking that the HIF-hypoxia signaling pathway is involved in the potential mechanism of Rha treatment of periodontitis and that it can bind stably to HIF1A. In vitro experiments, based on the hypoxia-induced inhibition of proliferation, migration, and osteogenic differentiation of hPDLSCs, we found that Rha inhibited the expression of HIIF1A, promoted the expression of PCNA, CXCR4, and OCN, and enhanced their proliferation, migration, and osteogenic differentiation. In in vitro experiments, Rha promoted alveolar bone repair and inhibited gingival inflammation in periodontitis rats. Rha is a potential drug for the treatment of periodontitis. Therefore, this study provides new insights into the potential mechanisms of Rha in periodontitis treatment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.